Novel chikungunya and dengue vaccines: travel medicine applications.

The article discusses the growing concern of arboviral diseases such as dengue and chikungunya in travelers. The United States has recently approved the world's first chikungunya vaccine, which has shown promising results in terms of seroresponse and clinical benefit. The article also highlights the increasing incidence of dengue in travelers and the availability of a new dengue vaccine. The recommendations for the use of these vaccines vary among different expert groups, but the authors argue for broader recommendations to address the high burden of these diseases. Further research is needed to gather more data on the vaccines' effectiveness, safety, and duration of protection. [Extracted from the article]